Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries's GHG Emissions Data Preview
In 2023, Sun Pharmaceutical Industries completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy), and Scope 3 (indirect emissions across the value chain).
Sun Pharmaceutical Industries has also provided a category-level breakdown for 7 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into Sun Pharmaceutical Industries's Operational Emissions
In 2023, the total operational greenhouse gas (GHG) emissions of Sun Pharmaceutical Industries amounted to 419,881 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Sun Pharmaceutical Industries increased by 0.16%, suggesting that the company faced challenges in reducing its emissions from its core operations.
Sun Pharmaceutical Industries's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Sun Pharmaceutical Industries's Scope 1 emissions?
In 2023, the total Scope 1 emissions of Sun Pharmaceutical Industries were 67,203 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Has Sun Pharmaceutical Industries reduced its Scope 1 emissions over time?
Since 2019, Sun Pharmaceutical Industries's Scope 1 emissions have decreased by 13.42%, reflecting a declining long-term trend in Scope 1 emissions over time.
Compared to the previous year (2022), Sun Pharmaceutical Industries's Scope 1 emissions decreased by 11.54%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.
What are Sun Pharmaceutical Industries's Scope 2 emissions?
In 2023, Sun Pharmaceutical Industries reported Scope 2 greenhouse gas (GHG) emissions of 352,678 tCOâ‚‚e without specifying the calculation method.
Has Sun Pharmaceutical Industries reduced its Scope 2 emissions over time?
Since 2019, Sun Pharmaceutical Industries's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Sun Pharmaceutical Industries 's emissions have plateaued with no significant change in its energy consumption footprint.
Compared to the previous year (2022), Sun Pharmaceutical Industries's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Sun Pharmaceutical Industries 's emissions have plateaued with no significant change in its energy consumption footprint.
What methodology does Sun Pharmaceutical Industries use for Scope 2 reporting?
In 2023, Sun Pharmaceutical Industries reported its Scope 2 emissions using an unspecified methodology.
Sun Pharmaceutical Industries's Scope 2 Emissions Over Time
- Total Scope 2 (Unspecified Calculation Method)
Insights into Sun Pharmaceutical Industries's Value Chain Emissions
In 2023, Sun Pharmaceutical Industries reported 357,266 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.
The 2023 disclosure of Sun Pharmaceutical Industries includes a breakdown across 7 of the 15 Scope 3 categories defined by the GHG Protocol, up from 6 in 2022, reflecting improved emissions accounting practices and greater transparency across the company's value chain
Sun Pharmaceutical Industries's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Sun Pharmaceutical Industries's Scope 3 emissions?
In 2023, Sun Pharmaceutical Industries reported total Scope 3 emissions of 357,266 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.
Compared to the previous year (2022), Sun Pharmaceutical Industries's Scope 3 emissions increased by 57.46%, suggesting that the company faced challenges in reducing emissions across its value chain.
What categories of Scope 3 emissions does Sun Pharmaceutical Industries disclose?
In 2023, Sun Pharmaceutical Industries reported emissions for 7 out of the 15 Scope 3 categories defined by the GHG Protocol.
This partial disclosure allows for some insight into the company's indirect impacts.
What are the main sources of Sun Pharmaceutical Industries's Scope 3 emissions?
In 2023, the largest contributors to Sun Pharmaceutical Industries's Scope 3 emissions were:
- Purchased Goods and Services (Cat. 1): 182,980 tCOâ‚‚e (51.22%)
- Fuel- and Energy-Related Services (Cat. 3): 99,161 tCOâ‚‚e (27.76%)
- Downstream Transportation and Distribution (Cat. 9): 38,311 tCOâ‚‚e (10.72%)
Sun Pharmaceutical Industries's Scope 3 Emissions by Categories
Insights into Sun Pharmaceutical Industries's Total Carbon Footprint
In 2023, Sun Pharmaceutical Industries reported a total carbon footprint of 777,147 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 20.28% increase compared to 2022, suggesting a rise in emissions across its operations or value chain.
The largest contributor to Sun Pharmaceutical Industries's total carbon footprint was Scope 3 emissions, accounting for 45.97% of the company's total carbon footprint, followed by Scope 2 emissions at 45.38%.